07.11.2014 Views

Growing Rich - Arabictrader.com

Growing Rich - Arabictrader.com

Growing Rich - Arabictrader.com

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

KIRK KAZANJIAN<br />

research manager was supposed to be the economist, editor, and team<br />

leader as well. So Stovall collected writings from noted bank economists,<br />

sifted through them, and came up with a summary of what<br />

they thought. It was pretty rudimentary, but it worked.<br />

In no time, Stovall was promoted to industrial analyst, this at a<br />

time when analysts had little visibility or status on Wall Street. “Securities<br />

analysts, as a group, were just starting to organize and it<br />

wasn’t even considered to be a legitimate profession,” Stovall offers.<br />

“I think the first meeting of the New York Society of Security Analysts<br />

was in somebody’s living room in 1939. They were then on hiatus<br />

during World War II. Things didn’t get rolling again until the late<br />

1940s. The Chartered Financial Analyst program wasn’t started until<br />

the early 1960s. I got my CFA as fast as I could in 1965. The CFA<br />

designation and its programs have helped the profession to gain much<br />

more recognition and professionalism.”<br />

THE POLIO REPORT<br />

As a junior analyst for E. F. Hutton in early 1955, Stovall scored<br />

a major coup after learning from a journalist friend that the Food<br />

and Drug Administration was about to approve the first-ever vaccine<br />

against the deadly polio virus. Word was that it had been discovered<br />

by a team led by Jonas Salk, a researcher at the University of Pittsburgh.<br />

The reporter claimed the government was withholding this<br />

announcement until the anniversary of President Franklin Delano<br />

Roosevelt’s death in April 1955. “I decided to write a report on the<br />

drug <strong>com</strong>panies that would likely be licensed to market the Salk polio<br />

vaccine,” Stovall says. “My fellow Wall Street drug analysts either<br />

didn’t know or didn’t care about this discovery. I figured if the government<br />

was going to announce the approval anyway, I would beat<br />

the herd by re<strong>com</strong>mending Merck, Parke-Davis, American Home<br />

Products, and a small California outfit called Cutter Laboratories beforehand.”<br />

When the announcement was made, Stovall’s re<strong>com</strong>mended<br />

stocks went up almost instantly. To the brokers who followed his<br />

advice, Stovall became a hero. “They thought I was a genius,” he exclaims.<br />

“But I was really an opportunistic rookie. I followed this up<br />

by re<strong>com</strong>mending Syntex, the first <strong>com</strong>pany to <strong>com</strong>e out with a birthcontrol<br />

drug.”<br />

These stellar re<strong>com</strong>mendations also helped to further his own career.<br />

78

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!